Check for updates

# The HMCES DNA-protein cross-link functions as an intermediate in DNA interstrand cross-link repair

Daniel R. Semlow<sup>1</sup>, Victoria A. MacKrell<sup>1</sup> and Johannes C. Walter<sup>2,3</sup>

The 5-hydroxymethylcytosine binding, embryonic stem-cell-specific (HMCES) protein forms a covalent DNA-protein cross-link (DPC) with abasic (AP) sites in single-stranded DNA, and the resulting HMCES-DPC is thought to suppress double-strand break formation in S phase. However, the dynamics of HMCES cross-linking and whether any DNA repair pathways normally include an HMCES-DPC intermediate remain unknown. Here, we use *Xenopus* egg extracts to show that an HMCES-DPC forms on the AP site generated during replication-coupled DNA interstrand cross-link repair. We show that HMCES cross-links form on DNA after the replicative CDC45-MCM2-7-GINS (CMG) helicase has passed over the AP site, and that HMCES is subsequently removed by the SPRTN protease. The HMCES-DPC suppresses double-strand break formation, slows translesion synthesis past the AP site and introduces a bias for insertion of deoxyguanosine opposite the AP site. These data demonstrate that HMCES-DPCs form as intermediates in replication-coupled repair, and they suggest a general model of how HMCES protects AP sites during DNA replication.

NA abasic (AP) sites are common genomic lesions that arise from spontaneous DNA depurination/depyrimidination or as intermediates in the excision of damaged nucleobases by DNA glycosylases. When formed in double-stranded DNA, AP sites are usually incised by base excision repair factors (AP endonucleases and AP lyases), generating a one nucleotide gap that is filled in by DNA polymerase  $\beta$  (ref. <sup>1</sup>). AP sites are also susceptible to spontaneous cleavage through a  $\beta$ -elimination mechanism<sup>2</sup>. Enzymatic or spontaneous cleavage of AP sites located in ssDNA, for example during DNA replication, results in the formation of a DNA double-strand break (DSB), which introduces the potential for gross chromosomal rearrangements. Cortez and colleagues demonstrated that the 5-hydroxymethylcytosine binding, embryonic stem-cell-specific (HMCES) protein associates with replication forks, covalently cross-links to ssDNA AP sites and suppresses accumulation of DSBs in cells treated with agents that induce AP site formation<sup>3</sup>. Structural evidence indicates that the conserved SRAP domain of HMCES specifically cross-links to AP sites positioned in ssDNA in vitro through formation of a thiazolidine linkage<sup>4-7</sup>. Taken together, these observations indicate that HMCES stabilizes ssDNA AP sites during replication through formation of a DNA-protein cross-link (DPC).

HMCES-DPC formation also appears to suppress mutagenic bypass of AP sites by translesion synthesis (TLS). Loss of HMCES increases association of the REV1-Pol $\zeta$  TLS polymerase with replication forks and increases the mutagenicity of ultraviolet- (UV-) induced DNA damage<sup>3,8</sup>. Additionally, HMCES depletion slows replication forks on induction of AP sites, and this defect is reversed by inhibition of REV1-Pol $\zeta$  or depletion of the TLS polymerase Polk (ref. <sup>9</sup>). These data indicate that HMCES antagonizes AP site bypass by TLS polymerases and promotes a more rapid, error-free bypass mechanism, possibly involving template switching. HMCES-DPC formation has so far been examined in the context of (1) cellular treatment with genotoxic agents that indirectly induce AP site formation by introducing a range of DNA damage<sup>3,8</sup> or (2) ectopic expression of APOBEC3A, which deaminates deoxycytosine to deoxyuracil that is in turn converted to an AP site by uracil DNA glycosylase<sup>9,10</sup>. In the former case, the identity of the DNA lesions that are encountered during replication and trigger HMCES action remain unknown. In the latter case, HMCES accumulates on chromatin independently of replication<sup>9</sup>, leaving open the mechanism by which these HMCES-DPCs form. In both cases, it is unclear whether HMCES-DPCs are only formed ad hoc when a pre-existing AP site is located in the DNA template, or whether they are generated constitutively as part of any DNA repair pathways that involve an AP site intermediate.

AP sites can also react with exocyclic amines of nucleobases on the opposite strand to generate highly toxic DNA interstrand cross-links (ICLs)<sup>11,12</sup>. These AP-ICLs covalently link the two strands of DNA and block DNA replication and transcription. During replication, AP-ICLs are repaired by the NEIL3 DNA glycosylase<sup>13</sup>. This pathway is activated when the convergence of two replication forks on either side of the ICL stimulates ubiquitylation of the replicative CDC45-MCM2-7-GINS (CMG) helicase (Fig. 1a and ref. 14). NEIL3 is recruited to ubiquitylated CMGs and unhooks the ICL by cleaving an N-glycosyl bond in the lesion, regenerating an AP site. The leading strand of one fork encounters the AP site and is then extended past the lesion in a REV1-dependent manner<sup>13</sup>. If the NEIL3 pathway fails to unhook the ICL, CMG is eventually unloaded by the p97 segregase<sup>15</sup> and the Fanconi anemia pathway unhooks the ICL through nucleolytic incisions, converting the ICL into a DSB that is subsequently repaired by homologous recombination<sup>16-18</sup>. The NEIL3 pathway is prioritized over the Fanconi anemia pathway, likely because NEIL3 avoids DSB formation and thus minimizes the

<sup>&</sup>lt;sup>1</sup>Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, USA. <sup>2</sup>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Blavatnik Institute, Boston, MA, USA. <sup>3</sup>Howard Hughes Medical Institute, Boston, MA, USA. <sup>See</sup>-mail: dsemlow@caltech.edu; johannes\_walter@hms.harvard.edu

### **NATURE STRUCTURAL & MOLECULAR BIOLOGY**



**Fig. 1] HMCES** cross-links to AP sites during NEIL3-dependent ICL repair. **a**, Model of replication-coupled ICL repair pathways. **b**, Schematic of repair products. Asel and Xhol digestion allows resolution of the top (87 nucleotides (nt)) and bottom (85 nt) strands. AP-ICL unhooking by NEIL3 generates an AP site that cross-links to HMCES and generates a discrete adduct in the top strand after proteinase K digestion. **c**, Detection of AP site adducts by strand-specific Southern blotting. pCtrl or pICL<sup>AP</sup> was replicated in egg extract. The p97i was added to prevent activation of the Fanconi anemia pathway. At the indicated times, DNA was isolated, treated with proteinase K and digested with Asel and Xhol. The repair products were separated on a denaturing polyacrylamide sequencing gel and visualized by Southern blotting with the indicated strand-specific probes. Size markers were generated by replicating pCtrl and pICL<sup>AP</sup> in extracts supplemented with [ $\alpha$ -<sup>32</sup>P]dATP, which generates radiolabeled nascent strands that were similarly processed and resolved on the same sequencing gel. **d**, HMCES immunodepletion. The extracts used in the replication reactions shown in **e** were blotted for HMCES. Asterisk, nonspecific band. **e**, pICL<sup>AP</sup> was replicated using the extracts in **d** and supplemented with p97i and rHMCES, as indicated. Repair products were visualized by body labeling or strand-specific Southern blotting as in **c**.

potential for genome instability<sup>14,19</sup>. NEIL3 does, however, introduce a labile ssDNA AP site, the fate of which is unknown.

Here, we used *Xenopus* egg extracts to show that a HMCES-DPC efficiently forms during AP-ICL repair. We exploited this system to study the dynamics of HMCES cross-linking to DNA and its subsequent removal. We find that after replisome stalling at an AP-ICL and ICL unhooking by NEIL3, CMG translocates beyond the newly generated AP site followed by HMCES reaction with the AP site. Leading strand collision with the HMCES-DPC then triggers DPC degradation by the replication-coupled protease SPRTN. Functionally, the HMCES-DPC suppresses DSB formation, slows TLS past the AP site and promotes insertion of deoxyguanosine opposite the AP site. Our results show that

HMCES-DPCs participate as a bona fide intermediate in DNA repair, and they show a general model for the generation and resolution of HMCES-DPCs at the DNA replication fork.

#### Results

**HMCES forms a DPC during NEIL3-dependent ICL repair.** We speculated that HMCES might cross-link to the AP site generated during NEIL3-dependent ICL repair. To test this idea, we replicated an undamaged control plasmid (pCtrl) or an AP-ICL-containing plasmid (pICL<sup>AP</sup>) in *Xenopus* egg extracts. A DNA fragment encompassing the ICL was excised, and the top and bottom strands were resolved on a denaturing polyacrylamide gel and visualized by strand-specific Southern blotting (Fig. 1b). Before electrophoresis,

the DNA was treated with proteinase K to convert any DPC formed to a short peptide adduct that is predicted to cause a discrete mobility shift<sup>20</sup>. To prevent formation of DNA adducts generated through nucleolytic ICL unhooking by the Fanconi anemia pathway, replication reactions were supplemented with the p97 inhibitor NMS-873 (p97i), which blocks CMG unloading and activation of the Fanconi anemia pathway<sup>13-15</sup>. As expected, replication of both pCtrl and pICL<sup>AP</sup> yielded only unmodified bottom strands (Fig. 1b,c, lanes 15-24). In contrast, while pCtrl replication produced only an unmodified top strand, pICLAP replication produced an additional, slower-migrating top strand species, consistent with the presence of a peptide adduct (Fig. 1c, lanes 27-36). After HMCES depletion (Fig. 1d), the slower-migrating top strand disappeared and it reappeared with addition of active, recombinant HMCES (rHMCES) (Fig. 1e, lanes 12-14 and Extended Data Fig. 1a,b). In contrast, addition of HMCES protein harboring a C2A mutation (rHMCES<sup>C2A</sup>) that blocks formation of the AP site thiazolidine linkage did not support formation of the slow-migrating top strand (Fig. 1e, lane 15, Extended Data Fig. 1b and ref.<sup>4</sup>). We conclude that HMCES cross-links to the AP site-containing top strand during AP-ICL repair, leading to formation of a covalent HMCES DNA intermediate.

We wanted to determine the efficiency of HMCES-DPC formation. After replication-coupled ICL repair, half of the top strands derive from the original cross-linked plasmid and contain an AP site that can be adducted by HMCES (Fig. 1b). Quantification of Fig. 1c shows that 25.3% of total top strands contained an adduct. Thus, at least 50.6% of parental top strands were cross-linked by HMCES. The actual efficiency of cross-linking might be higher since proteinase K treatment may not convert all HMCES-DPCs to a homogenous peptide adduct. We also examined the efficiency of HMCES cross-linking by measuring the sensitivity of replication intermediates to digestion with recombinant (r)APE1, which cleaves the phosphodiester backbone 5' of an AP site, but not when the AP site is cross-linked by HMCES3. pICLAP was replicated in mock- or HMCES-depleted extract, and repair intermediates were recovered and digested with HincII and rAPE1 (Extended Data Fig. 1c). Since NEIL3-dependent unhooking introduces an AP site in only one of the two daughter plasmids, we expected no more than 50% of plasmids to be cleaved by rAPE1 in the absence of HMCES13. At the 45-minute timepoint, only a fraction of plasmids recovered from mock-depleted extract was cleaved on treatment with rAPE1 (13.9% of total plasmids and 27.8% of AP site-containing plasmids, Extended Data Fig. 1d-f). HMCES depletion resulted in a dramatic increase in the fraction of plasmids cleaved by rAPE1 (49.6% of total plasmids and 99.2% of AP site-containing plasmids, Extended Data Fig. 1d-f). This cleavage was suppressed by the addition of rHM-CES, but not rHMCES<sup>C2A</sup>. Assuming that the difference in rAPE1 cleavage efficiency between samples recovered from mock- and HMCES-depleted extract reflects the efficiency of HMCES-DPC formation, we estimate that HMCES-DPCs formed on roughly 71.4% (99.2-27.8%) of AP sites generated during NEIL3-dependent ICL repair. The time-dependent decline in rAPE1 susceptibility likely reflects placement of the AP site into dsDNA by TLS<sup>13</sup>. We conclude that an HMCES-DPC represents a major intermediate in AP-ICL repair that can protect the AP site from added APE1, consistent with replication-coupled formation of an irreversible thiazolidine linkage.

HMCES suppresses DSBs during NEIL3-dependent ICL repair. To determine how the HMCS-DPC affects AP-ICL repair, we replicated pICL<sup>AP</sup> in mock- or HMCES-depleted extracts supplemented with  $[\alpha^{-32}P]$ dATP and resolved replication intermediates on a native agarose gel (Fig. 2a and Extended Data Fig. 2a). As shown previously<sup>13</sup>, replication in mock-depleted extract resulted in convergence of replication forks at the ICL, resulting in a slow-migrating 'figure 8'

intermediate (Fig. 2a, lanes 1-8). Unhooking by NEIL3 then lead to the appearance of catenated daughter molecules, followed by the formation of open-circular products that were finally converted to supercoiled species after TLS. HMCES depletion did not noticeably alter the accumulation of replication intermediates or open-circular and supercoiled products (Fig. 2a, lanes 9-16). However, it did cause transient and low-level accumulation of a new species that comigrates with linearized plasmid and is consistent with cleavage of the AP site generated during unhooking (Fig. 2a and Extended Data Fig. 2b,c, red arrowheads). Disappearance of this linear species correlated with the appearance of radioactive products in the wells (Fig. 2a, blue arrowheads), suggesting that these well products comprise intermediates in DSB repair<sup>17</sup>. Formation of linear species and well products was suppressed by rHMCES but not rHMC-ES<sup>C2A</sup> (Fig. 2a, lanes 17-32). The bacterial HMCES ortholog YedK functions as an AP lyase when the N-terminal cysteine is mutated to alanine<sup>4</sup>. However, rHMCES<sup>C2A</sup> neither exhibited AP lyase activity when incubated with ssDNA AP site substrate (Extended Data Fig. 1b) nor enhanced AP site cleavage during ICL repair, which would have increased linear products (Fig. 2a). These results indicate that C2A mutation of the vertebrate SRAP domain fails to induce AP lvase activity. Addition of rHMCES<sup>APIP</sup> harboring amino acid substitutions that disrupt its conserved PCNA-interacting protein-box (PIP-box) motif<sup>3</sup> also partially suppressed linear species and well product formation (Extended Data Figs. 1a,b and 2d,e), indicating that HMCES binding to PCNA is not absolutely required to suppress DSBs during AP-ICL repair. HMCES depletion had no effect on replication of pCtrl or a plasmid with a cisplatin-ICL (pICL<sup>Pt</sup>) that is repaired by the Fanconi anemia repair pathway without formation of an AP site (Extended Data Fig. 2f,g). These results show that HMCES suppresses cleavage of the AP site by endogenous nuclease(s), preventing DSB formation during AP-ICL repair.

We next addressed whether formation of the linear species observed in HMCES-depleted extract depends on NEIL3 glvcosylase activity. To this end, we replicated pICLAP in NEIL3- and HMCES-depleted extract supplemented with p97i. This experimental setup led to the convergence of replication forks at the ICL but not unhooking due to the absence of NEIL3 (Fig. 2b(i,ii) and Extended Data Fig. 2h). To induce unhooking and AP site formation, we then added back wild-type recombinant NEIL3 (rNEIL3) or catalytically defective NEIL3 (rNEIL3<sup>K60A</sup>, ref. <sup>13</sup>) and resolved the DNA on a native agarose gel (Fig. 2b(iii,iv),c). As expected, addition of rNEIL3, but not rNEIL3K60A, resulted in rapid AP-ICL unhooking as indicated by conversion of cross-linked replication intermediates into open-circular and supercoiled products (Fig. 2c, lanes 16-30). Addition of rNEIL3, but not rNEIL3<sup>K60A</sup>, generated the linear species indicative of AP site cleavage (Fig. 2c, lanes 16-30). As seen in Fig. 2a, fewer linear species were generated in the presence of HMCES (Fig. 2c, lanes 1–15). We conclude that HMCES suppresses DSB formation during ICL repair by cross-linking to the AP site produced by NEIL3-dependent N-glycosyl bond cleavage.

To seek independent evidence for the generation of DNA damage in the absence of HMCES, we replicated pICL<sup>AP</sup> in mock- or HMCES-depleted egg extracts and measured CHK1 phosphorylation. CHK1 is phosphorylated by the kinase ataxia-telangiectasia and Rad3-related (ATR), whose activation depends on accumulation of ssDNA<sup>21</sup>. Replication of pICL<sup>AP</sup> in HMCES-depleted extract led to a marked increase in ATR-dependent CHK1 phosphorylation compared to mock-depleted extract (Fig. 2d, lanes 1–10 and Extended Data Fig. 3a–c). Addition of wild-type rHMCES, but not rHMCES<sup>C2A</sup>, suppressed CHK1 phosphorylation (Fig. 2d, lanes 11–20). Although these data do not exclude other modes of ATR activation, they are consistent with the idea that after AP site cleavage and DSB formation, DNA ends are resected to generate ssDNA, which stimulates CHK1 phosphorylation by ATR. In further agreement with this interpretation, HMCES depletion did not

### **NATURE STRUCTURAL & MOLECULAR BIOLOGY**



**Fig. 2 | HMCES suppresses DSB formation during NEIL3-dependent ICL repair. a**,  $pICL^{AP}$  was replicated with  $[\alpha^{-32}P]dATP$  in mock- or HMCES-depleted extracts supplemented with rHMCES<sup>WT</sup> or rHMCES<sup>C2A</sup>, as indicated. Replication intermediates were separated on a native agarose gel and visualized by autoradiography. SC, supercoiled; OC, open circular; WP, well products. Red arrowheads indicate linear species; blue arrowheads indicate well products. **b**, Experimental strategy to synchronize AP-ICL unhooking by NEIL3-depletion and add back. p97i is added to replication reactions to prevent CMG unloading and accumulate replication forks that have converged at the ICL. rNEIL3 is added to stalled forks to activate unhooking. **c**,  $pICL^{AP}$  was replicated with  $[\alpha^{-32}P]dATP$  as described in **b** using the NEIL3- or NEIL3- and HMCES-depleted extracts shown in Extended Data Fig. 2a. Replication intermediates were analyzed as in **a**. **d**,  $pICL^{AP}$  was replicated in mock- or HMCES-depleted egg extracts (shown in Extended Data Fig. 2g) supplemented with rHMCES, as indicated. Replication reactions were separated by SDS-PAGE and blotted for phospho-CHK1 and MCM6 (loading control).

stimulate CHK1 phosphorylation during replication of pCtrl or pICL<sup>Pt</sup> (Extended Data Fig. 3d,e). Together, these results provide further evidence that HMCES prevents DNA damage by shielding the AP site generated during AP-ICL repair.

We asked why only a small fraction of AP sites are converted to DSBs in the absence of HMCES (Fig. 2a). One explanation is that

the leading strand is usually extended beyond the AP site by TLS before AP site cleavage, placing the AP site in dsDNA and preventing DSB formation. However, this was not the case because REV1 depletion (Extended Data Fig. 4a) did not enhance DSB formation in the absence of HMCES (Extended Data Fig. 4b, lanes 15–28). REV1 depletion was successful because it blocked the conversion of

## ARTICLES



**Fig. 3 | HMCES-DPC formation does not impede CMG translocation. a**, Models for timing of HMCES-DPC formation. Left branch, HMCES-DPC formation precedes CMG bypass of the AP site, which is predicted to delay leftward leading strand approach to the AP site. Right branch, CMG bypass of AP site precedes HMCES-DPC formation, resulting in no delay in leftward leading strand approach. b, Top, Schematic of nascent strands generated during ICL repair. AfIIII cuts 147 nt to the left and 540 nt to the right of the ICL, respectively, generating characteristic -20 to -40 stall, -1 stall and strand extension products. Bottom, pICL<sup>AP</sup> was replicated with  $[\alpha^{-32}P]$ dATP and p97i in the indicated extracts (shown in Extended Data Fig. 4a). After 60 min, rNEIL3 was added and nascent DNA strands were isolated at the indicated times, digested with AfIIII and resolved by denaturing polyacrylamide gel electrophoresis. Top, middle and bottom panels show sections of the same gel to visualize extension, leftward leading strands and rightward leading strands, respectively. Contrast was adjusted to visualize rightward fork stall products **c**, The persistence of -20 to -40 stall product in **b** was quantified by dividing the summed intensities of the -20 to -40 stall product bands in each lane by the intensity of the leftward fork -1 stall product band. Quantifications were normalized to the accumulation of -20 to -40 stall products at the 0 min time timepoint relative to NEIL3 addition. Quantifications from two independent experiments are shown.

open-circular plasmid into closed supercoiled plasmid, consistent with a TLS defect (Extended Data Fig. 4b). These results indicate the existence of an alternative, redundant mechanism that suppresses AP site cleavage during ICL repair. The HMCES-DPC is therefore critical to suppress DSB formation during NEIL3-dependent ICL repair, but in its absence, partially overlapping mechanisms appear to perform the same function.

Evidence that HMCES cross-links form after CMG progression. We next addressed when HMCES cross-links to the AP site. After CMGs converge on an ICL and NEIL3 unhooks the lesion, CMGs translocate past the newly generated AP site, and the leading strand advances to and stalls at the -1 position, before undergoing TLS past the lesion (Fig. 1a). One scenario is that HMCES cross-links to the AP site before CMG moves beyond the AP site (Fig. 3a, left branch), in which case CMG would likely need to bypass the intact HMCES-DPC, as seen previously for the repair of a model HpaII- a restriction enzyme DPC<sup>22</sup>. Alternatively, HMCES might cross-link to the AP site after CMG departure (Fig. 3a, right branch). In the former scenario, HMCES should delay the approach of the nascent leading strand to the -1 position because CMG bypass of an intact DPC is a slow event<sup>22</sup> (Fig. 3a, left branch). In the latter scenario, HMCES should not affect leading strand approach to -1 (Fig. 3a, right branch). To distinguish between these models, we replicated pICLAP in NEIL3-depleted or NEIL3- and HMCES-depleted extract supplemented with p97i, added back rNEIL3 to activate unhooking (Extended Data Fig. 5a,b), and monitored the kinetics of leftward leading strand extension to the -1 position. HMCES depletion had no discernible effect on the timing of leading strand approach to -1 (Fig. 3b,c), showing that CMG translocation past the AP site is unaffected by HMCES. Moreover, the kinetics of nascent strand extension were indistinguishable for the leftward replication forks, which encounter an HMCES-DPC on the template strand, and the rightward forks, which do not (Fig. 3b, compare middle and bottom panels, and Fig. 3c), further indicating that CMG translocation is unaffected by the HMCES-DPC. These observations strongly indicate that HMCES cross-links to DNA after CMG has translocated past the AP site.

HMCES-DPC formation impedes TLS past the AP site. To determine whether HMCES impedes TLS past an AP site, we replicated pICLAP in mock-depleted or HMCES-depleted extract (Extended Data Fig. 5c) and analyzed nascent strand extension. To suppress the Fanconi anemia pathway, extracts were treated with p97i, which also disrupts ubiquitin dynamics in egg extract<sup>23</sup> and partially inhibits TLS. Under these conditions, replication in mock-depleted extract resulted in a diffuse smear of DNA just below the position of open-circular plasmid, likely due to resection of unligated nascent 5' ends on plasmids where TLS had not occurred (Fig. 4a, lanes 1–6). HMCES depletion decreased the abundance of the faster migrating open-circular species and increased the amount of supercoiled DNA (Fig. 4a, lanes 7–12), suggesting that TLS past the AP site proceeds more efficiently in the absence of an HMCES-DPC. Consistent with this interpretation, the -1 stall product of the rightward leading strand disappeared more rapidly in HMCES-depleted extract than in mock-depleted egg extract (Fig. 4b, lanes 1-12, black arrow and Fig. 4c), indicating that the HMCES-DPC impedes TLS past the AP site. Addition of rHMCES, but not rHMCES<sup>C2A</sup>, restored both

the accumulation of open-circular species and the delay in nascent strand extension (Fig. 4a-c). Combined with our other observations (Fig. 3), these data indicate that the HMCES-DPC forms after CMG translocates beyond the AP site but before TLS.

HMCES-DPCs alter the mutation signature of ICL repair. We next sequenced AP-ICL repair products to determine whether the HMCES-DPC influences the mechanism and mutagenicity of AP site bypass. AP-ICL plasmids were replicated in mock-depleted extract, HMCES-depleted extract or HMCES-depleted extract supplemented with rHMCES or rHMCES<sup>C2A</sup>, and deep sequencing was performed to determine which nucleotide is incorporated across from the AP site in each condition (Fig. 5a and Extended Data Fig. 6a-f). Since bypass of the AP site through a template-switching mechanism should yield products whose sequence is dictated by the nucleotide opposite the AP site<sup>24</sup> (Extended Data Fig. 6a, left branch), we also examined the effect of varying the base opposite the AP site. For each extract condition, we obtained >11,000 reads that were derived from the nascent DNA strand produced on bypass of the AP site (Fig. 5a, orange box and Extended Data Fig. 6b, orange box). In all conditions, the identity of the nucleobase opposite the AP-ICL did not influence which base was inserted (Extended Data Fig. 6g), indicating that TLS, and not template switching, was the dominant mode of AP site bypass. In mock-depleted extract, the purines dG and dA were the most common nucleotides inserted opposite the AP site (45.3% for dG, 36.6% for dA), while the pyrimidines dT (10.5%) and dC (7.7%) were inserted much less frequently (Fig. 5b). By contrast, in HMCES-depleted extract, dA comprised 75.2% of reads while dG dropped to 13.0% (Fig. 5b). Pyrimidines were still inserted in only a minor fraction of bypass events in the absence of HMCES (7.2% for dT and 4.6% for dC). Addition of wild-type rHMCES, but not rHMCES<sup>C2A</sup>, to HMCES-depleted extract restored the proportion of dG insertions to levels observed in mock-depleted extract (Fig. 5b). These results indicate that while the REV1-dependent TLS prefers to insert dA opposite an unprotected AP site (consistent with the 'A rule' for TLS polymerases), formation of an HMCES-DPC biases the insertion step in favor of dG incorporation. Our results identify dG point mutation as a characteristic signature of HMCES-DPC bypass by TLS.

The SPRTN protease promotes HMCES-DPC removal. Previous work showed that the proteasome and the SPRTN protease can promote replication-coupled degradation of a HpaII-DPC<sup>20,25</sup>. We therefore tested how these proteases contribute to removal of the HMCES-DPC. To this end, we replicated pICL<sup>AP</sup> in NEIL3-depleted or NEIL3- and SPRTN-depleted extract, which stalls replication forks on either side of the ICL (Fig. 6a,b). We then added back rNEIL3 to activate unhooking and recovered chromatin to monitor HMCES association by immunoblotting. Under the relatively stringent plasmid recovery conditions used, HMCES was only detected on addition of rNEIL3, indicating that stable association of HMCES with DNA requires an AP site and formation of a covalent DPC (Fig. 6c, compare lane 2 with 3 and lane 10 with 11). Compared to mock-depletion, SPRTN depletion led to robust accumulation of HMCES on chromatin (Fig. 6c, top panel, compare lanes 3-5 and 11-13). In contrast, treatment with the proteasome inhibitor MG262 had no effect, either alone or in combination with SPRTN depletion (Fig. 6c, top panel). Efficient removal of

**Fig. 4 | HMCES-DPC formation impedes TLS. a**,  $plCL^{AP}$  was replicated with [ $\alpha$ -<sup>32</sup>P]dATP and p97i in mock- or HMCES-depleted extracts (shown in Extended Data Fig. 5c) supplemented with rHMCES, as indicated. Replication intermediates were analyzed as in Fig. 2a. Orange arrowheads indicate degraded open-circular plasmids. **b**, Nascent DNA strands from the  $plCL^{AP}$  replication reactions shown in **a** were digested with AfIIII and EcoRI (which cut 143 and 307 nt to the left and right of the ICL, respectively) and analyzed as in Fig. 3b. **c**, The persistence of the rightward fork –1 stall product in **b** was quantified by dividing the intensity of the –1 stall product band in each lane by the intensity of the full-length extension product band. Quantifications were normalized to the accumulation of the –1 stall product at the 30 min time timepoint. Quantifications from three independent experiments are shown.

## ARTICLES





**Fig. 5 | The HMCES-DPC promotes dG insertion during TLS. a**, Diagram depicting the strand that is sequenced after NEIL3-dependent ICL repair. Blue and green arrows indicate PCR primers, the red asterisk indicates potential point mutation and the sequenced strand is boxed in orange. See Extended Data Fig. 6b for details of experimental strategy and plasmid design. **b**, The four pICL<sup>AP</sup> plasmids described in Extended Data Fig. 6b were pooled and replicated using the indicated extracts (shown in Extended Data Fig. 6d), and sequencing libraries were prepared as described in Extended Data Fig. 6b. The fraction of reads corresponding to insertion of a given nucleotide opposite the AP site is plotted for each extract condition. *n*, number of pooled nascent strand reads obtained for each condition (see Extended Data Fig. 6g for deconvolution of pooled reads). Next-generation sequencing read counts can be found in Supplementary Tables 2–5.

HMCES from chromatin was restored in SPRTN-depleted extract by addition of wild-type recombinant SPRTN (rSPRTN<sup>WT</sup>), but not catalytically inactive SPRTN (rSPRTN<sup>E89Q</sup>, ref. <sup>25</sup>; Extended Data Fig. 7a,b). These results indicate that SPRTN is the main protease that degrades HMCES-DPCs. HMCES association with chromatin was not detected during replication of pCtrl or pICL<sup>Pt</sup> (Extended Data Fig. 7c,d), providing further evidence that recovery of HMCES depends on a specific association with AP site-containing DNA. In the absence of SPRTN, HMCES formed a diffuse smear of higher molecular weight species that collapsed into a single band on treatment with the general deubiquitylating enzyme rUSP21 (Fig. 6c, compare top and bottom panels). This observation indicates that HMCES can undergo polyubiquitylation, but the failure of MG262 to stabilize HMCES suggests that this ubiquitylation does not target HMCES to the proteasome.

Given the inhibitory effect of HMCES on TLS (Fig. 4), we expected that blocking SPRTN-dependent HMCES-DPC proteolysis would slow TLS. While SPRTN depletion inhibited TLS past a previously characterized HpaII model DPC<sup>25</sup> (Extended Data Fig. 8a–d), it slightly accelerated TLS past the HMCES-DPC during AP-ICL repair (Extended Data Fig. 8a,b,e,f). This observation is consistent with a report that SPRTN can antagonize TLS by sequestering the TLS subunit POLD3 (ref. <sup>26</sup>) and suggests that regulation of TLS by SPRTN depends on DPC identity and context. Alternatively, in the absence of SPRTN, the HMCES-DPC might be slowly processed by an alternative protease (Discussion), leaving behind a different peptide adduct that is compatible with faster TLS. Either way, these results indicate that, although the HMCES-DPC delays AP site bypass, SPRTN-dependent proteolysis of HMCES is not a prerequisite for TLS past the cross-link.

Leading strand extension activates HMCES-DPC proteolysis. When the replisome collides with a HpaII-DPC, CMG first bypasses the DPC, whereafter extension of the nascent leading strand up to the DPC triggers SPRTN-dependent proteolysis<sup>22,25</sup>. Consistent with this observation, purified SPRTN preferentially targets DPCs positioned at a ssDNA-dsDNA junction<sup>27</sup>. We wanted to know whether degradation of the HMCES-DPC is also dependent on approach of the nascent DNA strand. pICL<sup>AP</sup> was replicated in NEIL3-depleted

extract supplemented with p97i, which caused leading strand stalling 20 to 40 nt from the ICL due to the footprint of the converged CMGs<sup>15</sup> (Figs. 3b and 6d). rNEIL3 was then added back to activate ICL unhooking in the presence or absence of the replicative polymerase inhibitor aphidicolin, which blocked leading strand extension to the ICL<sup>25,28</sup>. Chromatin was then recovered and blotted for HMCES. Compared to the dimethylsulfoxide (DMSO) control, aphidicolin greatly stabilized HMCES on chromatin (Fig. 6d, lanes 3–10). We conclude that SPRTN-dependent degradation of an HMCES-DPC is enhanced by approach of the leading strand, as seen during canonical repair of a HpaII DPC.

#### Discussion

Current models envision that HMCES cross-links to pre-existing AP sites when these are encountered by the replication fork, but it has been unclear whether HMCES-DPC formation occurs as part of any DNA repair pathway involving an AP site intermediate. Here, we show that an HMCES-DPC is formed during the repair of DNA ICLs. We exploit this observation to characterize the dynamics of HMCES cross-linking to DNA during replication and its effect on repair. Our data indicate that once the AP-ICL is unhooked by NEIL3 and CMG translocates past the newly formed AP site, HMCES cross-links to the AP site and protects it from cleavage. Subsequent extension of the leading strand to the HMCES-DPC triggers SPRTN-dependent HMCES proteolysis. When it is bypassed by TLS, the adduct introduces a bias for deoxyguanosine insertion opposite the AP site. Our results reveal an unexpected coupling of ICL and DPC repair pathways that suppresses DSB formation, and they suggest a unified model to explain how HMCES is deployed during DNA replication to preserve genome stability.

The timing and context of HMCES-DPC formation. Our data indicate that HMCES cross-links to the AP site after CMG has traveled beyond the unhooked ICL and before TLS occurs. In support of this model, HMCES does not influence the rapid kinetics of leading strand extension to the AP site (Fig. 3), indicating that CMG does not need to bypass an intact HMCES-DPC (Fig. 7). Although we cannot rule out that CMG bypass of an HMCES-DPC is so fast that it does not delay leading strand extension, two additional lines of evidence

## ARTICLES



**Fig. 6 | SPRTN degrades HMCES-DPCs formed during ICL repair. a**, Potential mechanisms of HMCES-DPC proteolysis during ICL repair. **b**, NEIL3 and SPRTN immunodepletion. The extracts used in the replication reactions shown in **c** were blotted for NEIL3 and SPRTN. Asterisks, nonspecific bands. **c**, pICL<sup>AP</sup> was replicated in the indicated egg extracts supplemented with p97i for 60 min. Reactions were then treated with the proteasome inhibitor MG262 (or DMSO control) and rNEIL3 to promote ICL unhooking. Chromatin was recovered under stringent conditions, DNA was digested and released proteins were separated by SDS-PAGE and blotted for HMCES. Top panel, chromatin was directly analyzed. Bottom panel, recovered chromatin was treated with the deubiquitylating enzyme USP21 before SDS-PAGE. Asterisks, nonspecific bands. **d**, Left, experimental strategy to explore role of nascent strand approach in HMCES proteolysis. pICL<sup>AP</sup> was replicated in NEIL3-depleted egg extract supplemented with p97i for 60 min. Reactions were then treated with the polymerase inhibitor aphidicolin (or DMSO control) and rNEIL3 to allow for ICL unhooking. Right, chromatin was recovered under the indicated conditions and analyzed as in **c**. Asterisk, nonspecific band.



**Fig. 7 | Model for AP site protection by HMCES during NEIL3-dependent ICL repair.** Fork convergence at an ICL activates NEIL3-dependent unhooking and introduces an AP site in the leading strand template. The AP site is bypassed by CMG but stalls DNA polymerase, resulting in uncoupling of DNA unwinding from leading strand synthesis by Pole. This exposes the AP site at a ssDNA-dsDNA junction, where it is cross-linked by HMCES. The ssDNA-dsDNA junction abutting the HMCES-DPC activates proteolysis by SPRTN, but the resulting peptide adduct continues to stabilize the AP site until the lesion is bypassed by TLS. HMCES-DPC formation introduces a bias for dG insertion opposite the AP site.

suggest that HMCES-DPC formation is slower than CMG translocation past the AP site. First, the accumulation of HMCES-DPCs is delayed by several minutes relative to ICL unhooking (Fig. 1c, compare accumulation of unhooked strands with accumulation of the adducted top strand). Second, even in the presence of HMCES, a substantial fraction of recovered AP-ICL repair intermediates is initially susceptible to cleavage by exogenous APE1 (Extended Data Fig. 1e,f, compare the 30- and 45-min timepoints). Taken together, these data indicate that HMCES-DPC formation protects AP sites generated by ICL unhooking only after a delay of several

### **NATURE STRUCTURAL & MOLECULAR BIOLOGY**

minutes, whereas CMG departure after ICL unhooking should be immediate (Fig. 3). On the other hand, the HMCES-DPC clearly delays the already slow leading strand extension beyond the AP site (Fig. 4). Therefore, the HMCES-DPC probably forms after CMG departure but before TLS. Since leading strand extension up to the AP site should be almost instantaneous after ICL unhooking and CMG departure, we propose that HMCES cross-links the AP site at a ssDNA-dsDNA junction (Fig. 7). This model is consistent with recent structural and biochemical studies using a bacterial SRAP domain, which suggest that an SRAP-DPC can accommodate a nascent strand at the AP site4,6,7. As seen for purified HMCES3,4 (Extended Data Fig. 1b), HMCES in egg extracts can also cross-link to AP sites in a fully ssDNA region when nascent strand approach is blocked using aphidicolin (Fig. 6d). HMCES cross-linking therefore exhibits a degree of flexibility that should allow it to protect AP sites encountered on either the leading or lagging strands.

What causes AP site cleavage in the absence of HMCES? In the absence of HMCES, AP site cleavage could occur either spontaneously (due to  $\beta$ -elimination) or via enzymatic action. Spontaneous  $\beta$ -elimination is unlikely to be the main source of AP site cleavage because the AP site remains intact during extensive workup of ICL repair intermediates (for example, Extended Data Fig. 1c-f), suggesting that it is relatively stable. On the other hand, numerous enzymes present in egg extract can catalyze strand incision at an AP site. These enzymes include AP endonucleases such as APEX1, which cleaves most AP sites in cells29. Although APEX1 has a strong preference for dsDNA AP sites, it has substantial activity on ssDNA AP sites<sup>30</sup>. However, knocking down APEX1 and APEX2 in mammalian cells did not suppress DSB formation in the absence of HMCES, suggesting that AP endonuclease are not responsible for AP site cleavage during replication<sup>9</sup>. ssDNA AP sites could also be cleaved by one or more AP lyases present in cells that catalyze strand incision at an AP site through Schiff base formation followed by β-elimination, a reaction that HMCES is expected to repress<sup>4</sup>. In the future, it will be important to identify the enzyme(s) that promote DSB formation in the absence of HMCES.

**Redundant mechanisms that suppress AP site cleavage?** In the absence of HMCES, only a small fraction of AP sites underwent cleavage during ICL repair, even when AP site bypass was blocked (Figs. 2 and 3). This suggests that ssDNA AP sites are stabilized by one or more redundant mechanisms. ssDNA at converged replication forks is probably bound by replication protein A (RPA), which could nonspecifically occlude AP endonuclease/lyase activity. A DNA polymerase, such as Pol  $\delta$ , could also bind the 3' end of nascent DNA at the AP site and occlude enzymatic AP site cleavage. Alternatively, ssDNA AP sites might be protected by a more specialized DNA binding activity analogous to the Shu complex, which suppresses AP site-induced genome instability in yeast<sup>31</sup>. It will be interesting to determine whether an analogous Rad51 paralog complex contributes to AP site stability during DNA replication in vertebrates.

The interplay of HMCES with lesion bypass. Previous reports indicate that HMCES antagonizes TLS and promotes error-free bypass of AP sites in human cells, although the underlying mechanism is unknown<sup>3,8,9</sup>. Our results show that while HMCES slows the kinetics of REV1-dependent AP site bypass, the adduct is eventually overcome by TLS and there is no error-free bypass via template switching. We speculate that the TLS impediment posed by HMCES helps promote error-free bypass in mammalian cells. However, error-free bypass does not occur in egg extracts, possibly because extracts lack a critical factor needed for this pathway or because small plasmids replicated in egg extract lack sufficient sister chromatid cohesion to enable template switching. TLS past the

## ARTICLES

AP site position did not require SPRTN-dependent proteolysis of the HMCES-DPC (Extended Data Fig. 7), suggesting that TLS can accommodate an intact HMCES-DPC. This accommodation may be facilitated by structural features of the HMCES SRAP domain. The SRAP domain of YedK interacts with only seven nucleotides along ssDNA and the covalent thiazolidine linkage is formed by the extreme N terminus of the protein<sup>4,6,7</sup>. HMCES may therefore be able to transiently undock from ssDNA while remaining covalently tethered to an AP site, effectively behaving as a peptide adduct that can be accommodated in a TLS polymerase active site. Following TLS, the HMCES-DPC is no longer located at a ssDNA-dsDNA junction and therefore would not be processed by SPRTN. In this scenario, the HMCES-DPC may be removed by an alternative protease, such as the proteasome or DDI2 (below).

Given that purines are more susceptible to spontaneous hydrolysis of the *N*-glycosyl bond (depurination) and oxidative damage requiring base excision repair, we anticipated that the HMCES-DPC might minimize mutagenesis by promoting pyrimidine insertion opposite an AP site. We were therefore surprised to find that HMCES-DPC formation introduces a bias for dG insertion opposite the adducted AP site. This HMCES-dependent bias for dG insertion during TLS may indicate an inherent thermodynamic constraint imposed on TLS polymerase during DPC bypass, akin to the 'A rule' observed for insertion opposite an unprotected AP site. Alternatively, dG insertion bias may indicate that the SRAP domain evolved to suppress mutagenesis from cytosine deamination, which leads to the formation of AP sites by uracil DNA glycosylase.

The mechanism of HMCES-DPC removal. We showed that during ICL repair in egg extract, HMCES-DPC proteolysis depended on SPRTN but not the proteasome. As seen for a model HpaII-DPC<sup>25</sup>, HMCES-DPC proteolysis by SPRTN required extension of the nascent leading strand to the DPC, which places the DPC at a ssDNA-dsDNA junction (Fig. 6d). Activation by nascent strand approach is therefore likely a general feature of SPRTN-dependent proteolysis, consistent with biochemical data indicating that human SPRTN activation requires a ssDNA-dsDNA junction<sup>27</sup>. In human cells, the proteasome inhibitor MG132 stabilizes HMCES on chromatin, suggesting that HMCES-DPCs can be degraded by the proteasome<sup>3</sup>. While the relative efficiencies of SPRTN- and proteasome-dependent proteolysis may differ in egg extracts and mammalian cells, proteasome inhibition may indirectly inhibit SPRTN-dependent HMCES proteolysis in cells. For example, proteasome inhibition might overwhelm the SPRTN-dependent pathway by increasing the total number of DPCs encountered during replication. Alternatively, because proteasome inhibition disrupts ubiquitin dynamics, it might also interfere with ubiquitin-dependent regulation of SPRTN activity<sup>32</sup>.

HMCES-DPCs accumulated as polyubiquitylated species that were still processed at an appreciable rate when both SPRTN and the proteasome were inhibited (Fig. 6c), suggesting the existence of an alternative HMCES-processing pathway. Recently, it was reported that *Saccharomyces cerevisiae* Ddi1 (the homolog of vertebrate DDI2) removes a subset of DPCs in cells and that it can partially compensate for loss of the SPRTN homolog Wss1 (ref. <sup>33</sup>). Moreover, Ddi1 was also shown to be activated by long polyubiquitin chains in vitro<sup>34</sup>. Recent experiments performed in egg extracts have demonstrated that the E3 ubiquitin ligase RFWD3 polyubiquitylates an HMCES-DPC in an engineered ssDNA region of a circular plasmid<sup>35</sup>. Taken together, these observations indicate that RFWD3-dependent polyubiquitylation of an HMCES-DPC may induce DDI2-dependent proteolysis.

A general model for HMCES action during DNA replication. Our data show that an HMCES-DPC is an intermediate of AP-ICL repair; it forms after CMG translocates beyond the unhooked ICL, and it protects the newly formed ssDNA AP site until after it is rendered double-stranded by TLS (Fig. 7). We suggest that a similar mechanism operates when replication forks encounter pre-existing AP sites. We propose that when the AP site is located in the leading strand template, CMG passes over the lesion and leading strand synthesis stalls at the lesion (Extended Data Fig. 9(i)). As seen during AP-ICL repair, HMCES cross-links to the AP site at the ssDNAdsDNA junction. Although HMCES is immediately proteolyzed by SPRTN (Extended Data Fig. 9(iii,iv)), the HMCES thiazolidine cross-link is sufficient to protect the AP site during the vulnerable period before TLS (Extended Data Fig. 9(iv,v)). A related mechanism would operate when forks encounter AP sites on the lagging strand template (Extended Data Fig. 9(ii)). As before, CMG rapidly translocates past the AP site, but due to the time required to initiate a new Okazaki fragment, the HMCES-DPC probably forms in a fully ssDNA context. Nevertheless, the HMCES-DPC is likely to be short-lived because it will be degraded when extension of an Okazaki fragment triggers SPRTN-dependent HMCES degradation. In all cases, HMCES-DPC formation delays TLS past the AP site and potentially allows for engagement of an error-free bypass mechanism.

#### **Online content**

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/ s41594-022-00764-0.

Received: 13 July 2021; Accepted: 28 March 2022; Published online: 9 May 2022

#### References

- Krokan, H. E. & Bjørås, M. Base excision repair. Cold Spring Harb. Perspect. Biol. 5, a012583 (2013).
- Lindahl, T. Instability and decay of the primary structure of DNA. *Nature* 362, 709–715 (1993).
- Mohni, K. N. et al. HMCES maintains genome integrity by shielding abasic sites in single-strand DNA. Cell 176, 144–153.e13 (2019).
- Thompson, P. S., Amidon, K. M., Mohni, K. N., Cortez, D. & Eichman, B. F. Protection of abasic sites during DNA replication by a stable thiazolidine protein-DNA cross-link. *Nat. Struct. Mol. Biol.* 26, 613–618 (2019).
- Aravind, L., Anand, S. & Iyer, L. M. Novel autoproteolytic and DNA-damage sensing components in the bacterial SOS response and oxidized methylcytosine-induced eukaryotic DNA demethylation systems. *Biol. Direct* 8, 20 (2013).
- Halabelian, L. et al. Structural basis of HMCES interactions with abasic DNA and multivalent substrate recognition. *Nat. Struct. Mol. Biol.* 26, 607–612 (2019).
- Wang, N. et al. Molecular basis of abasic site sensing in single-stranded DNA by the SRAP domain of *E. coli* yedK. *Nucleic Acids Res.* 47, 10388–10399 (2019).
- Srivastava, M. et al. HMCES safeguards replication from oxidative stress and ensures error-free repair. EMBO Rep. 21, e49123 (2020).
- Mehta, K. P. M., Lovejoy, C. A., Zhao, R., Heintzman, D. R. & Cortez, D. HMCES maintains replication fork progression and prevents double-strand breaks in response to APOBEC deamination and abasic site formation. *Cell Rep.* 31, 107705 (2020).
- Biayna, J. et al. Loss of the abasic site sensor HMCES is synthetic lethal with the activity of the APOBEC3A cytosine deaminase in cancer cells. *PLoS Biol.* 19, e3001176 (2021).
- Price, N. E. et al. Interstrand DNA-DNA cross-link formation between adenine residues and abasic sites in duplex DNA. J. Am. Chem. Soc. 136, 3483–3490 (2014).
- Semlow, D. R. & Walter, J. C. Mechanisms of vertebrate DNA interstrand cross-link repair. *Annu. Rev. Biochem.* https://doi.org/10.1146/ annurev-biochem-080320-112510 (2021).
- Semlow, D. R., Zhang, J., Budzowska, M., Drohat, A. C. & Walter, J. C. Replication-dependent unhooking of DNA interstrand cross-links by the NEIL3 glycosylase. *Cell* 167, 498–511.e14 (2016).
- 14. Wu, R. A. et al. TRAIP is a master regulator of DNA interstrand crosslink repair. *Nature* 567, 267–272 (2019).

### **NATURE STRUCTURAL & MOLECULAR BIOLOGY**

- Fullbright, G., Rycenga, H. B., Gruber, J. D. & Long, D. T. p97 Promotes a conserved mechanism of helicase unloading during DNA cross-link repair. *Mol. Cell. Biol.* 36, 2983–2994 (2016).
- Knipscheer, P. et al. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. *Science* 326, 1698–1701 (2009).
- Long, D. T., Räschle, M., Joukov, V. & Walter, J. C. Mechanism of RAD51-dependent DNA interstrand cross-link repair. *Science* 333, 84–87 (2011).
- Räschle, M. et al. Mechanism of replication-coupled DNA interstrand crosslink repair. Cell 134, 969–980 (2008).
- Li, N. et al. Cooperation of the NEIL3 and Fanconi anemia/BRCA pathways in interstrand crosslink repair. Nucleic Acids Res. 48, 3014–3028 (2020).
- Duxin, J. P., Dewar, J. M., Yardimci, H. & Walter, J. C. Repair of a DNA-protein crosslink by replication-coupled proteolysis. *Cell* 159, 346–357 (2014).
- Cimprich, K. A. & Cortez, D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 9, 616–627 (2008).
- 22. Sparks, J. L. et al. The CMG helicase bypasses DNA-protein cross-links to facilitate their repair. *Cell* **176**, 167–181.e21 (2019).
- Rycenga, H. B., Wolfe, K. B., Yeh, E. S. & Long, D. T. Uncoupling of p97 ATPase activity has a dominant negative effect on protein extraction. *Sci. Rep.* 9, 10329 (2019).
- Conti, B. A. & Smogorzewska, A. Mechanisms of direct replication restart at stressed replisomes. DNA Repair 95, 102947 (2020).
- Larsen, N. B. et al. Replication-coupled DNA-protein crosslink repair by SPRTN and the proteasome in *Xenopus* egg extracts. *Mol. Cell* 73, 574–588.e7 (2019).

- Kim, M. S. et al. Regulation of error-prone translesion synthesis by Spartan/ Clorf124. Nucleic Acids Res. 41, 1661–1668 (2013).
- 27. Reinking, H. K. et al. DNA structure-specific cleavage of DNA-protein crosslinks by the SPRTN protease. *Mol. Cell* **80**, 102–113.e6 (2020).
- Long, D. T., Joukov, V., Budzowska, M. & Walter, J. C. BRCA1 promotes unloading of the CMG helicase from a stalled DNA replication fork. *Mol. Cell* 56, 174–185 (2014).
- 29. Li, M. & Wilson, D. M. Human apurinic/apyrimidinic endonuclease 1. *Antioxid. Redox Signal* **20**, 678–707 (2014).
- Marenstein, D. R., Wilson, D. M. & Teebor, G. W. Human AP endonuclease (APE1) demonstrates endonucleolytic activity against AP sites in single-stranded DNA. *DNA Repair* 3, 527–533 (2004).
- Rosenbaum, J. C. et al. The Rad51 paralogs facilitate a novel DNA strand specific damage tolerance pathway. *Nat. Commun.* 10, 3515 (2019).
- Stingele, J. et al. Mechanism and regulation of DNA-protein crosslink repair by the DNA-dependent metalloprotease SPRTN. *Mol. Cell* 64, 688–703 (2016).
- Serbyn, N. et al. The aspartic protease Ddi1 contributes to DNA-protein crosslink repair in yeast. Mol. Cell 77, 1066–1079.e9 (2020).
- 34. Yip, M. C. J., Bodnar, N. O. & Rapoport, T. A. Ddil is a ubiquitin-dependent protease. *Proc. Natl Acad. Sci. USA* **117**, 7776–7781 (2020).
- Gallina, I. et al. The ubiquitin ligase RFWD3 is required for translesion DNA synthesis. *Mol. Cell* 81, 442–458.e9 (2021).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2022

#### Methods

Sequences of oligonucleotides mentioned in methods can be found in Supplementary Table 1. All unique materials are available from commercial suppliers or are available on request from the authors.

**Statistics and reproducibility.** The experiments described in Figs. 1c–e, 2a,c,d, 3b,c, 5b and 6b–d and Extended Data Figs. 1a,b,d–f, 2a–h, 3a–e, 4a,b, 5a–c, 6c–g, 7c,d and 8a–f were performed twice and representative results are shown. The experiments described in Fig. 4a–c and Extended Data Fig. 7a,b were performed three times and representative results are shown. No statistical methods were used to predetermine sample size. Experiments were not randomized, and the investigators were not blinded to allocation during experiments and outcome assessment.

Preparation of oligonucleotide duplexes with site-specific ICLs. Site-specific cross-links were prepared as previously described<sup>13,36</sup>. To generate the Pt-ICL-containing oligonucleotide duplex, 1 mM cisplatin was converted to activated monoaquamonochloro cisplatin by incubation in 10 mM NaClO<sub>4</sub>, 0.95 mM AgNO<sub>3</sub> for 24 h at 37 °C in the dark. Cisplatin monoadduct was then generated by incubating 0.125 mM Pt-ICL top oligonucleotide in 5.63 mM 10 mM NaClO<sub>4</sub>, 0.375 mM monoaquamonochloro cisplatin (in activation mixture) for 12 min at 37 °C. The reaction was quenched by addition of NaCl to 0.1 M. The monoadducted oligonucleotide was then purified with a Mono Q 5/50 GL column using a gradient from 370 mM to 470 mM NaCl in 10 mM NaOH over 40 column volumes. Fractions containing the monoadducted oligonucleotide were pooled and adjusted to 2 mM MgCl<sub>2</sub>. Then 1.05 molar equivalents of Pt-ICL bottom oligonucleotide were added and buffer exchange was performed with 100 mM NaClO<sub>4</sub> using an Amicon Ultra-15 3 K filter unit at 4 °C. The oligonucleotides in 100 mM NaClO<sub>4</sub> were allowed to cross-link by incubation at 37 °C for 48 h. The cross-linked oligonucleotide duplex was then purified with a Mono Q 5/50 GL column using a gradient from 550 mM to 700 mM NaCl in 10 mM NaOH over 40 column volumes. Fractions containing the Pt-ICL duplex were pooled and buffer exchange was performed into 10 mM Tris-HCl (pH 7.4), 10 mM NaClO<sub>4</sub> using an Amicon Ultra-15 mL 3K MWCO filter unit at 4°C. The cross-link was stored at -80 °C. To generate AP-ICL-containing oligonucleotide duplexes, the appropriate complementary oligonucleotides (AP-ICL top and AP-ICL bottom; AP-ICL top and AP-ICL<sup>rev</sup> bottom; AP/A top and AP/A bottom; AP/G top and AP/G bottom; AP/T top and AP/T bottom; AP/C top and AP/C bottom) were annealed in 30 mM HEPES-KOH (pH 7.0), 100 mM NaCl by heating to 95 °C for 5 min and cooling at 1 °Cmin<sup>-1</sup> to 18 °C. The annealed duplex was then treated with uracil glycosylase (NEB) in 1× UDG buffer (20 mM Tris-HCl, 10 mM dithiothreitol (DTT), 10 mM EDTA (pH 8.0)) for 120 min at 37 °C followed by extraction with phenol:chloroform:isoamyl alcohol (25:24:1; pH 8) and ethanol precipitation. The duplex was then dissolved in 50 mM HEPES-KOH (pH 7.0), 100 mM NaCl and incubated at 37 °C for 5-7 d to allow cross-link formation. Cross-linked DNA was purified on a 20% polyacrylamide, 1× Tris-borate-EDTA (TBE), 8 M urea gel. The cross-linked products visualized by UV shadowing, eluted from crushed gel slices into TE (pH 8.0), extracted with phenol:chloroform:isoamyl alcohol (25:24:1; pH 8) and ethanol precipitated. The cross-links were dissolved in 10 mM Tris-HCl (pH 8.5) and stored at -80 °C.

Preparation of plasmids containing cross-links (pICL). Plasmids containing ICLs were prepared as described previously<sup>13,36,37</sup>. Briefly, the backbone plasmid (with or without 48 lacO repeats) was digested with BbsI in NEBuffer 2.1 for 24 h at 37 °C followed by extraction with phenol:chloroform:isoamyl alcohol (25:24:1; pH8) and ethanol precipitation. The linearized plasmid was dissolved in TE (pH 8.0) and purified over a HiLoad 16/60 Superdex 200 column using isocratic flow of TE (pH 8.0). Fractions containing the digested plasmid were pooled, ethanol precipitated and dissolved in 10 mM Tris-HCl (pH 8.5). The ICL-containing duplexes were ligated into the plasmid backbone using 400 U ml-1 NEB T4 DNA ligase in 1× ligase buffer (50 mM Tris-HCl (pH7.5), 10 mM MgCl<sub>2</sub>, 1 mM ATP, 10 mM DTT) at room temperature for 24 h. The ligation reactions were concentrated using Qiagen 500-tips and DNA was eluted with 1.25 M NaCl, 50 mM Tris-HCl (pH 8.5). The DNA was dialyzed into TE (pH 8.0) and concentrated with an Amicon Ultra-15 10 K filter unit. CsCl was added to the DNA to a homogenous solution density of 1.6 g ml<sup>-1</sup> and ethidium bromide was added to 50 µg ml<sup>-1</sup> The DNA was then transferred to a Quick-Seal tube and spun for 23 h at 20 °C in an NVT-90 rotor at 446,730g. The covalently closed circular plasmid was collected and extracted with an equal volume of saturated isobutanol to remove ethidium bromide. The DNA was then dialyzed into TE (pH 8.0), concentrated with an Amicon Ultra-15 mL 10K MWCO filter unit, and snap frozen and stored at -80 °C. pICL<sup>AP</sup> was used for the experiments shown in Figs. 1c-e, 2a,c and 3b,c and Extended Data Figs. 1c-f, 2b,c and 3. pICL-lacOAP was used for the experiments shown in Figs. 2d and 6b-d and Extended Data Figs. 2d-k, 5c and 6. pICL-lacO<sup>AP-rev</sup> was used for the experiments shown in Figs. 4a-c and Extended Data Figs. 4 and 7b,e,f. pDPCme, used for the experiments shown in Extended Data Fig. 7b-d, was a gift from J. Sparks and was prepared as described previously<sup>22</sup>.

**Preparation of** *Xenopus* egg extracts. Animal work performed at Harvard Medical School was approved by the Harvard Medical Area Standing Committee

on Animals (HMA Institutional Animal Care and Use Committee (IACUC) Study ID IS00000051-3, approved 25 October 2017). The institution has an approved Animal Welfare Assurance (no. A3431-01) from the National Institutes of Health (NIH) Office of Laboratory Animal Welfare. Animal work performed at Caltech was approved by the IACUC (Protocol IA20-1797, approved 28 May 2020). The institution has an approved Animal Welfare Assurance (no. D16-00266) from the NIH Office of Laboratory Animal Welfare. Preparation of high-speed supernatant (HSS) and nucleoplasmic extracts (NPE) from Xenopus laevis eggs was performed as described previously38. Briefly, HSS was prepared from eggs collected from six laboratory bred wild-type adult female X. laevis (aged >2 years). Eggs were dejellied in 11 of 2.2% (w/v) cysteine, pH 7.7, washed with 21 0.5× Marc's Modified Ringer's solution (2.5 mM HEPES-KOH (pH 7.8), 50 mM NaCl, 1 mM KCl, 0.25 mM MgSO<sub>4</sub>, 1.25 mM CaCl<sub>2</sub>, 0.05 mM EDTA) and washed with 11 of Egg Lysis Buffer (ELB) (10 mM HEPES-KOH (pH 7.7), 50 mM KCl, 2.5 mM MgCl<sub>2</sub>,  $250\,mM$  sucrose,  $1\,mM$  DTT and  $50\,\mu g\,ml^{-1}$  cycloheximide). Eggs were then packed in 14-ml round-bottom Falcon tubes at 180g using a Sorvall ST8 swinging bucket rotor. Eggs were supplemented with 5 µg ml<sup>-1</sup> aprotinin, 5 µg ml<sup>-1</sup> leupeptin and 2.5 µg ml-1 cytochalasin B and then crushed by centrifugation at 20,000g for 20 min at 4 °C in a TH13-6×50 rotor using a Sorvall Lynx 4000 centrifuge. The low-speed supernatant (LSS) was collected by removing the soluble extract layer and supplemented with 50 µg ml<sup>-1</sup> cycloheximide, 1 mM DTT, 10 µg ml<sup>-1</sup> aprotinin,  $10 \,\mu g \,ml^{-1}$  leupeptin and  $5 \,\mu g \,ml^{-1}$  cytochalasin B. This extract was then spun in thin-walled ultracentrifuge tubes at 260,000g for 90 min at 2 °C in a TLS 55 rotor using a tabletop ultracentrifuge. Lipids were aspirated off the top layer, and HSS was harvested, aliquoted, snap frozen in liquid nitrogen and stored at -80 °C. NPE preparation also began with extracting LSS, except eggs were collected from 20 laboratory bred wild-type female X. laevis (aged >2 years), and the volumes used to dejelly and wash the eggs were doubled (21 of 2.2% cysteine, 41 of 0.5× Marc's Modified Ringer's solution and 21 of ELB). LSS was supplemented with 50 µg ml-1 cycloheximide, 1 mM DTT, 10 µg ml<sup>-1</sup> aprotinin, 10 µg ml<sup>-1</sup> leupeptin, 5 µg ml<sup>-</sup> cytochalasin B and 3.3 µg ml<sup>-1</sup> nocodazole. The LSS was then spun at 20,000g for 15 min at 4 °C in a TH13-6×50 rotor using a Sorvall Lynx 4000 centrifuge. The top, lipid layer was removed, and the cytoplasm was transferred to a 50-ml conical tube. ATP regenerating mix (2 mM ATP, 20 mM phosphocreatine and 5 µg ml-1 phosphokinase) was added to the extract. Nuclear assembly reactions were initiated by adding demembranated X. laevis sperm chromatin<sup>39</sup> to a final concentration of 4,400 µl<sup>-1</sup>. After 75–90 min incubation, the nuclear assembly reactions were centrifuged for 3 min at 18,000g at 4 °C in a TH13-6x50 rotor using a Sorvall Lynx 4000 centrifuge. The top, nuclear layer was then harvested and spun at 260,000g for 30 min at 2 °C in a TLS 55 rotor using a tabletop ultracentrifuge. Finally, lipids were aspirated off the top layer, and NPE was harvested, aliquoted, snap frozen in liquid nitrogen and stored at -80 °C.

Protein expression and purification. A PCR fragment containing the X. laevis HMCES sequence with C-terminal FLAG tag was obtained by amplifying an IDT gBlock containing the HMCES coding sequence with primers HMCES F and HMCES R. NEBuilder HiFi DNA assembly master mix was used according to the manufacturer's instructions to insert the HMCES PCR fragment into a pFastBac1 backbone that had been amplified with primers FB1-FLAG F and FB1-FLAG R. The sequence of pFastBac1-HMCES-FLAG was confirmed by Sanger sequencing. The C2A mutation was introduced by quick change mutagenesis using primers HMCES C2A F and HMCES C2A R and the sequence of pFastBac1-HMCES-FLAG C2A was confirmed by Sanger sequencing. The W321A L322A mutations were introduced by inverse PCR using primers HMCES W321A L322A F and HMCES W321A L322A R and the sequence of pFastBac1-HMCES-FLAG W321A L322A was confirmed by Sanger sequencing. Baculoviruses expressing the rHMCES-FLAG proteins were then prepared using the Bac-to-Bac system according to the manufacturer's protocols. HMCES-FLAG proteins were expressed in 250 ml of suspension cultures of Sf9 cells (Expression Systems) by infection with baculovirus expressing rHMCES-FLAG for 72 h. Sf9 cells were collected and suspended in 8 ml of lysis buffer (50 mM Tris-HCl (pH7.5), 300 mM NaCl, 5% glycerol, 1× cOmplete protease inhibitors, 0.5 mM PMSF, 0.2% [v/v] Triton X-100). Cells were lysed by sonication and the soluble fraction was collected by spinning the lysate at 68,000g for 1 h. The soluble lysate was incubated with 200 µl of anti-FLAG M2 affinity resign for 90 min at 4 °C. The resin was washed once with 10 ml of lysis buffer, twice with wash buffer (50 mM Tris-HCl (pH 7.5), 300 mM NaCl, 5% glycerol, 0.2% (v/v) Triton X-100) and three times with buffer 50 mM Tris-HCl (pH 7.5), 300 mM NaCl, 5% glycerol. HMCES-FLAG proteins were eluted from the resin with 50 mM Tris-HCl (pH 7.5), 300 mM NaCl, 5% glycerol, 100 µg ml<sup>-1</sup> 3× FLAG peptide. Fractions containing rHMCES-FLAG proteins were dialyzed against 50 mM Tris-HCl (pH8.0), 150 mM NaCl, 10% glycerol, 10 mM DTT at 4°C overnight and then again for 4 h at 4°C. Aliquots of protein were snap frozen and stored at -80 °C.

Biotinylated LacI was expressed and purified essentially as described previously<sup>40</sup>. Briefly, LacI with a C-terminal AviTag and biotin ligase were coexpressed in T7 Express Cells supplemented with 50 μM biotin from pET11a[LacR-Avi] and pBirAcm (Avidity) vectors, respectively. AviTag-LacI and biotin ligase expression were induced with 1 mM isopropyl-β-D-thiogalactoside (IPTG) in media supplemented with 50 μM biotin to ensure efficient biotinylation

of the AviTag-LacI. Cell pellets were lysed for 30 min at room temperature in lysis buffer containing 50 mM Tris-HCl (pH7.5), 5 mM EDTA, 100 mM NaCl, 1 mM DTT, 10% sucrose (w/v), 1× cOmplete protease inhibitors, 0.2 mg ml<sup>-1</sup> lysozyme, 0.1% Brij 58. The insoluble fraction was pelleted by centrifugation at 21,300g for 1 h at 4 °C in an Eppendorf 5424 R centrifuge. Chromatin-bound LacI was then suspended in 50 mM Tris-HCl (pH7.5), 5 mM EDTA, 1 M NaCl, 30 mM IPTG, 1 mM DTT and released from the DNA by sonication followed by addition of polymin P to 0.03-0.06 % (w/v) at 4 °C. LacI was then precipitated with 37% ammonium sulfate, pelleted by centrifugation, and resuspended in buffer containing 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 2.6 M NaCl, 1 mM DTT nad 1× cOmplete protease inhibitors. Next, biotinylated LacI was bound to with SoftLink avidin resin for 90 min at 4 °C, washed with 50 mM Tris-HCl (pH7.5), 1 mM EDTA, 2.6 M NaCl, 1 mM DTT, 1× cOmplete protease inhibitors and eluted with 50 mM Tris-HCl (pH7.5), 100 mM NaCl, 1 mM EDTA, 5 mM biotin and 1 mM DTT. Pooled fractions containing LacI were buffer exchanged into 50 mM Tris-HCl (pH7.5), 150 mM NaCl, 1 mM EDTA, 1 mM DTT using an Amicon Ultra-0.5 mL 3K MWCO filter unit. LacI aliquots were snap frozen in liquid nitrogen and stored at -80 °C.

X. laevis rNEIL3-FLAG and rNEIL3-FLAG K60A were expressed and purified as described previously13. Briefly, baculoviruses expressing rNEIL3-FLAG were prepared using the Bac-to-Bac system (Thermo Fisher Scientific) according to the manufacturer's protocols. rNEIL3-FLAG protein was expressed in 250 ml of Sf9 insect cell cultures by infection with baculovirus expressing NEIL3-FLAG for 48 h at 27 °C. Sf9 cells were collected and suspended in 10 ml of lysis buffer (50 mM Tris-HCl (pH 7.5), 300 mM NaCl, 10% [v/v] glycerol, 1× cOmplete protease inhibitors, 0.5 mM PMSF, 0.2% [v/v] Triton X-100). Cells were lysed by sonication, and the soluble fraction was collected by spinning the lysate at 106,883g in a Beckman SW41 rotor for 1 h at 4 °C. The soluble lysate was incubated with 200 µl of anti-Flag M2 affinity resin for 90 min at 4 °C. The resin was washed once with 10 ml of Lysis Buffer, twice with 50 mM Tris-HCl (pH 7.5), 300 mM NaCl, 10% glycerol, 0.2% (v/v) Triton X-100) and three times with 50 mM Tris-HCl (pH 7.5), 300 mM NaCl, 10% glycerol. rNEIL3-FLAG protein was eluted from the resin with 50 mM Tris-HCl (pH7.5), 300 mM NaCl, 10% glycerol, 100 µg ml-1 3×FLAG peptide. Fractions containing rNEIL3-FLAG protein were pooled and dialyzed against 50 mM HEPES-KOH (pH7.0), 300 mM NaCl, 1 mM DTT, 20% glycerol at 4°C for 12h and then dialyzed against 50 mM HEPES-KOH (pH7.0), 150 mM NaCl, 1 mM DTT, 15% glycerol at 4 °C for 3 h. Aliquots of protein were snap frozen and stored at -80°C.

rSPRTN-FLAG and rSPRTN-FLAG E89Q proteins were a gift from A. Gao and purified as described previously<sup>25</sup>. rUSP21 protein was a gift from D. Finley.

**Immunodepletions.** Immunodepletions using antibodies against HMCES, SPRTN, REV1 and NEIL3 were performed as described<sup>13,25,41</sup>. Briefly, protein A Sepharose Fast Flow beads were washed in 1× PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.8 mM KH<sub>2</sub>PO<sub>4</sub>) and then incubated with an appropriate volume of antibodies overnight at 4 °C (3 volumes for antibodies against HMCES, SPRTN and NEIL3; 1 volume for antibodies against REV1). The beads were then washed twice with 1× PBS, once with ELB, twice with 500 mM NaCl in ELB and thrice with ELB. Three rounds of immunodepletion were performed by adding 5 volumes of egg extract to 1 volume of beads and incubating on a rotating wheel at 4 °C for 60 min. In the case of REV1 depletion, two rounds were performed using the N-terminal antibody and one round was performed using the C-terminal antibody. Extracts were spun for 30 s at 622g in a S-24-11-AT rotor using an Eppendorf 5430R centrifuge and the supernatants were collected without disturbing the beads.

Replication reactions. Replication reactions were performed essentially as described previously<sup>39</sup>. Briefly, licensing was performed by incubating 7.5 ng µl-1 plasmid with HSS (supplemented with 3 µg ml-1 nocodazole, 20 mM phosphocreatine, 2 mM ATP and 5 µg ml<sup>-1</sup> creatine phosphokinase) for 30 min at room temperature (roughly 21 °C). Where indicated, licensing mixes were supplemented with 111-333 nM 3000 Ci per mmol [α-32P]dATP. Replication was initiated by adding 1 volume licensing mix to 2 volumes NPE mix (50% NPE, 20 mM phosphocreatine, 2 mM ATP and  $5\,\mu g\,ml^{-1}$  creatine phosphokinase, 4 mM DTT in ELB). Where indicated, replication reactions were supplemented with 100 nM rNEIL3-FLAG, 100-200 nM rHMCES-FLAG, 30 nM rSPRTN-FLAG, 200 µM NMS-873, 200 µM MG 262, 2 µM AZD6738 or 75 µM aphidicolin. For analysis on native agarose gels, reactions were stopped at indicated timepoints by mixing 1 µl of replication reaction mix with 6 µl of replication stop buffer (8 mM EDTA, 0.13% phosphoric acid, 10% ficoll, 5% SDS, 0.2% bromophenol blue, 80 mM Tris-HCl, pH 8.0) and then digested with 2.5 mg ml<sup>-1</sup> proteinase K for 60 min at 37 °C. The DNA was then resolved on 0.8% agarose, 1× TBE gels. The gels were dried and visualized by phosphorimaging. Autoradiograms were imaged with a Typhoon FLA 7000 (GE Healthcare) using the FujiFilm FLA 7000 v.1.12 user interface or a Typhoon FLA 9500 (GE Healthcare) using the FujiFilm FLA 9500 user interface v.1.1. Autoradiograms were analyzed using ImageJ v.1.52 or Image Lab v.6.4.0. For analysis of nascent DNA strands and strand-specific Southern blots, the replication reactions were stopped at indicated timepoints by mixing 4 µl of replication reaction mix with 40 µl of clear replication stop mix (50 mM Tris (pH 7.5), 0.5% SDS, 25 mM EDTA). Quenched reactions were then digested with

### **NATURE STRUCTURAL & MOLECULAR BIOLOGY**

0.2 mg ml<sup>-1</sup> RNaseA for 30 min at 37 °C and then with 2 mg ml<sup>-1</sup> proteinase K for 60 min at 37 °C. Samples were adjusted to 200  $\mu$ l with 10 mM Tris-HCl (pH 8.5), extracted twice with phenol:chloroform:isoamyl alcohol, extracted once with chloroform and ethanol precipitated. The recovered DNA was suspended in 10  $\mu$ l of 10 mM Tris-HCl (pH 8.5) and stored at -20 °C. For replications analyzed by APE1 digestion, 2.4  $\mu$ l of recovered DNA was incubated for 3 h at 37 °C with 4 U HincII and 4 U APE1, 1× NEBuffer 4 in a total of 4  $\mu$ l. Digestions were stopped with 8  $\mu$ l of replication stop buffer and resolved on a 0.8% agarose, 1× TBE gel.

Nascent strand analysis. Nascent strand analysis was performed as described<sup>18</sup>. Briefly, plasmid DNA was recovered from replication reactions as described above and 3µl of DNA was incubated for 3 h at 37 °C with 4 U AfIIII, 8 U EcoRI, 4 U FspI or 8 U AatII as indicated in a total volume of 5µl. Digestions were performed in 1× NEBuffer 3.1 or 1× NEB CutSmart buffer. Digestion reactions were stopped by addition of 2.5µl of gel loading buffer 2 (95% Formamide, 18 mM EDTA and 0.025% SDS, 0.025% xylene cyanol, 0.025% bromophenol blue). Samples were heated at 75 °C for 3 min, snap cooled on ice and resolved on 7% acrylamide (37.5:1), 8 M urea, 0.8× GTG buffer (71 mM Tris, 23 mM taurine, 0.4 mM EDTA) sequencing gels. The gels were dried and visualized by phosphorimaging. Autoradiograms were imaged with a Typhoon FLA 7000 (GE Healthcare) using the FujiFilm FLA 7000 v.1.12 user interface or a Typhoon FLA 9500 (GE Healthcare) using the FujiFilm FLA 9500 user interface v.1.1. Autoradiograms were analyzed using ImageJ v.1.52 or Image Lab v.6.4.0.

Strand-specific Southern blotting. Strand-specific Southern blot was performed essentially as previously described18. Briefly, 3 µl of plasmid DNA recovered from pICLAP replication reactions (as described above) was incubated at 37 °C for 3 h with 4 U AseI, 8 U XhoI, 1× NEBuffer 3.1 in a total volume of 5 µl. Digestion reactions were stopped by addition of 2.5 µl of gel loading buffer 2. Samples were heated at 75 °C for 3 min, snap cooled on ice and resolved on 8% acrylamide (19:1), 8 M urea, 0.8× GTG buffer sequencing gels. The gels were transferred to filter paper and then the DNA was transferred to Hybond-XL membrane in 0.5× TBE at 0.4 A using a Transblot SD semidry transfer cell. The membrane was washed with 4× SSC for 5 min and then cross-linked with 120,000 µJ cm<sup>-2</sup> 254 nm UV light. The membrane was incubated in 25 ml of Ultrahyb buffer for at least 6 h at 42 °C. The 85mer top strand probe and 87mer bottom strand probe were 5' end radiolabeled by incubating 0.2  $\mu$ M oligonucleotide with 0.2  $\mu$ M 3,000 Ci per mmol [ $\gamma$ -<sup>32</sup>P]ATP and 10 U T4 PNK in 1× NEB T4 PNK buffer for 30 min at 37 °C in a total volume of 50  $\mu l.$  The reaction was then heated to 65 °C for 20 min and passed through a Micro Bio-Spin Column with Bio-Gel P-6. The radiolabeled probe was added to the Ultrahyb buffer and incubated at 42 °C for 24 h. The membrane was washed twice with 2× SSC, 0.1% SDS at 42 °C for 5 min. The membranes were visualized by phosphorimaging. Autoradiograms were imaged with a Typhoon FLA 7000 (GE Healthcare) using the FujiFilm FLA 7000 v.1.12 user interface or a Typhoon FLA 9500 (GE Healthcare) using the FujiFilm FLA 9500 user interface v.1.1. Autoradiograms were analyzed using ImageJ v.1.52 or Image Lab v.6.4.0.

Plasmid pull down. Plasmid pulldowns to monitor the HMCES-DPC were performed essentially as previously described<sup>25</sup>. Briefly, streptavidin-coupled magnetic Dynabeads (10µl per pull down) were washed twice with 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA (pH 8.0), 0.02% Tween-20. Biotinylated LacI (0.4 pmol per 1 µl of beads) was added to the beads and incubated at room temperature for 40 min. The beads were then washed four times with DPC pull-down buffer (20 mM Tris pH 7.5, 150 mM NaCl, 2 mM EDTA pH 8, 0.5% IPEGAL-CA630) and then stored in the same buffer on ice until needed. At the indicated times, 8 µl of replication reaction was quenched into 400 µl of DPC pull-down buffer on ice. After all of the timepoints were quenched, 10 µl of LacI-coated streptavidin Dynabeads were added to each sample and allowed to bind for 30 min at 4 °C on a rotating wheel. The beads were then washed three times with DPC pull-down buffer and then twice with Benzonase buffer (20 mM Tris pH 7.5, 20 mM NaCl, 2 mM MgCl2, 0.02% Tween-20). Beads were suspended in 7.5  $\mu l$  of Benzonase buffer containing 250–300 U Benzonase and 2.5  $\mu M$  USP21. Beads were incubated for 1 h at 37 °C on a rotating wheel. The supernatant was collected and mixed with 7.5 µl of 2× Laemmli loading buffer and analyzed by immunoblotting.

**Immunoblotting.** Samples in 1× Laemmli loading buffer (generally equivalent to 1µl of replication reaction or chromatin recovered from 8µl of plasmid pull down) were resolved on 10% or 4–15% acrylamide Mini-PROTEAN or Criterion TGX precast gels (Bio-Rad) and transferred to polyvinyl difluoride membranes (Perkin Elmer). Membranes were blocked in 5% nonfat milk in 1× PBST (PBS with Tween) for 1 h at room temperature, rinsed several times with 1× PBST and then incubated with primary antibody diluted in 1× PBST overnight at 4°C with shaking. Primary antibody dilutions were as follows: Rabbit polyclonal anti-phospho-CHK1 (Ser345; human) Cell Signaling Technology catalog no. 2341, 1:500, Rabbit polyclonal anti-HMCES (*Xenopus*) New England Peptide Project 4377, 1:5,000; Rabbit polyclonal anti-NEIL3 (*Xenopus*) Abgent rabbit 57141, 1:5,000; Rabbit polyclonal anti-MCM6 (*Xenopus*) New England Peptide Project

## ARTICLES

2926, 1:2,500; Rabbit polyclonal anti-SPRTN (Xenopus) Pocono Rabbit Farm and Laboratory rabbit 31053, 1:5,000. The membranes were washed with three times in 1× PBST for 10–20 min at room temperature. The membranes were then incubated for 1 h at room temperature with goat anti-rabbit peroxidase-conjugate secondary antibody (IgG, H+L) Jackson ImmunoResearch catalog no. 111-035-003 or mouse anti-rabbit peroxidase-conjugate secondary antibody (IgG, Light Chain Specific) Jackson ImmunoResearch catalog no. 211-032-171 diluted 1:20,000 or 1:5,000, respectively, in 5% nonfat milk in 1× PBST. The membranes were washed three times in  $1 \times$  PBST for 10–20 min at room temperature. The membranes were then incubated with SuperSignal West Dura or ProSignal Pico Spray chemiluminescence substrate for 1-4 min at room temperature and imaged using an Amersham Imager 600 (GE Healthcare) or ChemiDoc (Bio-Rad) imaging systems. Contrast was occasionally adjusted to improve visualization of bands. Goat anti-rabbit peroxidase-conjugate secondary antibody (IgG, H+L) was manufacturer validated by antigen-binding assay, western blotting and/or enzyme-linked immunosorbent assay (ELISA). Mouse anti-rabbit peroxidase-conjugate secondary antibody (IgG, Light Chain Specific) was manufacturer validated by antigen-binding assay, western blotting and/or ELISA. Phospho-hCHK1 (ser345) antibody was manufacturer validated by western blot analysis of extracts from CV-1 in origin with SV40 gene cells treated with UV or methyl methanesulfonate. All antibodies against Xenopus proteins used in this study were validated by western blotting using Xenopus egg extracts. Immunoblots were imaged using an Amersham Imager 680 or a ChemiDoc Imaging System using the user interface v.2.4. Immunoblots were analyzed using ImageJ v.1.52 or Image Lab v.6.4.0.

Denaturing gel shift assays. AP-ICL top oligonucleotide was 5' end radiolabeled by incubating 0.2  $\mu$ M oligonucleotide with 0.2  $\mu$ M 3,000 Ci per mmol [ $\gamma$ -<sup>32</sup>P] ATP and 20 U T4 PNK in 1× NEB T4 PNK buffer for 30 min at 37 °C in a total volume of  $50\,\mu l.$  The reaction was then heated to  $65\,^o\!C$  for  $20\,min$  and passed through a Micro Bio-Spin Column with Bio-Gel P-6. The labeled oligonucleotide was extracted with phenol:chloroform:isoamyl alcohol (25:24:1; pH 8) and precipitated in ethanol. The labeled oligonucleotide (roughly 5 pmol) was treated with uracil glycosylase (NEB) in 1× UDG buffer (20 mM Tris-HCl, 10 mM DTT, 10 mM EDTA (pH 8.0)) for 120 min at 37 °C followed by extraction with phenol:chloroform:isoamyl alcohol (25:24:1; pH 8) and ethanol precipitation. 1 nM oligonucleotide was incubated with 50 nM rHMCES-FLAG protein in 10 mM Tris-HCl (pH 8.0), 50 mM NaCl, 10 mM MgCl<sub>2</sub>, 0.1 mg ml<sup>-1</sup> BSA, 2 mM DTT for 1 h at 37 °C. Then 3 µl of reaction was guenched into 15 µl of 86% (v/v) formamide, 1× TBE, 20 mM EDTA, 0.25% (w/v) bromophenol blue and resolved on a 10% polyacrylamide (19:1), 8 M Urea, 1× TBE gel. The gels were visualized by phosphorimaging. Autoradiograms were imaged with a Typhoon FLA 7000 (GE Healthcare) using the FujiFilm FLA 7000 v.1.12 user interface or a Typhoon FLA 9500 (GE Healthcare) using the FujiFilm FLA 9500 user interface v.1.1. Autoradiograms were analyzed using ImageJ v.1.52 or Image Lab v.6.4.0.

Preparation of sequencing libraries. Pooled pICLAP-X plasmids were replicated in mock- or HMCES-depleted egg extract supplemented with rHMCES-FLAG for 3h at room temperature as described above. The 10-ul reactions were quenched with 100 µl of clear replication stop mix (50 mM Tris (pH 7.5), 0.5% SDS, 25 mM EDTA). Quenched reactions were then digested with 0.2 mg ml<sup>-1</sup> RNaseA for 30 min at 37 °C and then with 2 mg ml<sup>-1</sup> proteinase K for 60 min at 37 °C. Samples were adjusted to 400 µl with 10 mM Tris-HCl (pH 8.5), extracted twice with 400 µl of phenol:chloroform:isoamyl alcohol, extracted once with 400 µl of chloroform and ethanol precipitated. The recovered DNA was suspended in 22 µl of 10 mM Tris-HCl (pH 8.5). The DNA was then digested with 5 U of Nt.BstNBI in  $25 \,\mu$ l of 1× NEBuffer 3.1 for 1 h at 55 °C and then for 20 min at 80 °C. Samples were adjusted to 150 µl with 10 mM Tris-HCl (pH 8.5), extracted twice with 150 µl of phenol:chloroform:isoamyl alcohol, extracted once with 150 µl of chloroform and ethanol precipitated. The recovered DNA was suspended in 8µl of 10 mM Tris-HCl (pH 8.5). DNA (roughly 10 ng) was amplified in 100 µl containing 1× NEB Phusion buffer, 0.2 mM each dNTP, 2.5 µl of RA302 primer, 2.5 µM RA303 primer and 2 U NEB Phusion polymerase. Amplification reactions were incubated at 98 °C for 30 s followed by 18 cycles of incubation at 98 °C for 10 s, 55 °C for 30 s and 72 °C for 30 s, and then incubated at 72 °C for 10 min. The amplified products were inspected on a 1% agarose, 1× TBE gel stained with SYBR Gold, purified using the QIAquick PCR purification kit according to the manufacturer's instructions and submitted for next-generation amplicon sequencing by Genewiz.

**Reporting Summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

#### Data availability

All data supporting the findings of this study are available within the article and its Supplementary Information files. Sequencing read counts are available in Supplementary Tables 2–5. Source data showing unprocessed and uncropped gel and blot images are provided with this paper.

#### References

- Enoiu, M., Ho, T. V., Long, D. T., Walter, J. C. & Schärer, O. D. Construction of plasmids containing site-specific DNA interstrand cross-links for biochemical and cell biological studies. *Methods Mol. Biol.* 920, 203–219 (2012).
- Zhang, J. et al. DNA interstrand cross-link repair requires replication-fork convergence. *Nat. Struct. Mol. Biol.* 22, 242–247 (2015).
- Sparks, J. & Walter, J. C. Extracts for analysis of DNA replication in a nucleus-free system. *Cold Spring Harb. Protoc.* https://doi.org/10.1101/pdb. prot097154 (2019).
- Lebofsky, R., Takahashi, T. & Walter, J. C. DNA replication in nucleus-free Xenopus egg extracts. Methods Mol. Biol. 521, 229–252 (2009).
- Dewar, J. M., Budzowska, M. & Walter, J. C. The mechanism of DNA replication termination in vertebrates. *Nature* 525, 345–350 (2015).
- Budzowska, M., Graham, T. G., Sobeck, A., Waga, S. & Walter, J. C. Regulation of the Rev1-pol ζ complex during bypass of a DNA interstrand cross-link. *EMBO J.* 34, 1971–1985 (2015).

#### Acknowledgements

We thank J. Campbell, W. Dunphy and members of the Semlow and Walter laboratories for comments on the manuscript. D.R.S. is supported by NIH grant no. GM129422. J.C.W. is supported by NIH grant no. HL098316 and gift from the family of J.G. Wiseman. D.R.S. is a Ronald and JoAnne Willens Scholar. J.C.W. is a Howard Hughes Medical Institute Investigator and an American Cancer Society Research Professor.

#### Author contributions

D.R.S. performed all experiments except those described in Fig. 2a and Extended Data Figs. 1a,b and 2a–g, which were performed by V.A.M. D.R.S. and J.C.W. designed the experiments, analyzed the data and wrote the paper.

#### **Competing interests**

D.R.S. and V.A.M. declare no competing interests. J.C.W. is a cofounder of MOMA Therapeutics, in which he has a financial interest.

#### Additional information

**Extended data** are available for this paper at https://doi.org/10.1038/s41594-022-00764-0.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41594-022-00764-0.

Correspondence and requests for materials should be addressed to Daniel R. Semlow or Johannes C. Walter.

**Peer review information** *Nature Structural & Molecular Biology* thanks Orlando Schärer and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Beth Moorefield was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Reprints and permissions information is available at www.nature.com/reprints.